Clinical trials: Gastrointestinal Malignancy
Hepatocellular Carcinoma
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Circulating free cell DNA (cfDNA) is extracellular fragmentation of nucleic acids that occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic cells or the lysis of circulating tumor cells…
- Trial name
- NCT02036216
- Where
- 2 sites in United States, China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Lynch Syndrome, Colon Cancer
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2…
- Conditions
- Lynch Syndrome, Colon Cancer, Colon Neoplasm
- Trial name
- MesaCAPP (NCT04920149)
- Testing
- Mesalamine
- Where
- 8 sites in Denmark, Sweden
- Volunteers
- 150 people
- Sponsor
- Ann-Sofie Backman
Early Gastric Cancer
The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer
The gastric cancer is the second most frequently diagnosed cancer and the third leading cause of cancer death in China.80%-90% patients were detected at middle and later stage.The five-year survival rate for advanced gastric…
- Trial name
- NCT02710838
- Testing
- infrared endoscopy
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
Colorectal Cancer
Ginger for Colorectal Cancer Prevention
The purpose of this study is to determine if ginger root extract when taken daily for 28 days is able to decrease levels of inflammatory chemicals called eicosanoids in the gut tissue of people who are at normal risk and those at…
- Trial name
- NCT01344538
- Testing
- Ginger Root Extract (Pure Encapsulations)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
IACS-010759 in Advanced Cancers
This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03291938
- Testing
- Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Depression, Anxiety Disorder
Probiotics for Depression in Cancer Patients
Anxiety and depressive disorders are quite prevalent in the general population. In 2015, it was estimated that 3.6% of the world population (around 264 million individuals) live with depression and 4.4% (around 322 million) with…
- Conditions
- Depression, Anxiety Disorder, Probiotics, Gastrointestinal Cancer
- Trial name
- NCT06496438
- Testing
- Psychobiotics
- Where
- Greece
- Volunteers
- 270 people
- Sponsor
- Aristotle University Of Thessaloniki
Moderate Mitral Regurgitation
Moderate Mitral Regurgitation in CABG Patients
Background: The presence of a mild to moderate ischemic mitral regurgitation (IMR) results in a significantly reduced long-term survival and increased hospitalizations for heart-failure.
- Trial name
- MoMIC (NCT00613548)
- Testing
- CABG alone, CABG + Mitral repair
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- University of Aarhus
Uterine Cervical Cancer, Uterine Cervix Cancer
Three Birds With One Stone
The overall aim of the study is to increase participation rates in cervical cancer (CCU) and colorectal cancer (CRC) screening programmes in Denmark by offering home-based CCU and CRC screening to women who are overdue for one or…
- Conditions
- Uterine Cervical Cancer, Uterine Cervix Cancer, Uterine Cervical Neoplasm, Colorectal Neoplasms
- Trial name
- NCT05022511
- Testing
- Screening status
- Where
- Denmark
- Volunteers
- 27,099 people
- Sponsor
- University of Aarhus
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer.
- Conditions
- EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT03087071
- Testing
- Laboratory Biomarker Analysis, Panitumumab, Trametinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer
The purpose of this study is to determine safety and to obtain preliminary estimates of the rate of major pathologic response of neoadjuvant accelerated fraction, standard dose radiation given with chemotherapy in patients with…
- Trial name
- NCT01333332
- Testing
- Capecitabine, Standard Dose Acclerated Fraction Radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Virginia
Advanced Solid Tumor, Metastatic Breast Cancer
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
- Conditions
- Advanced Solid Tumor, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
- Trial name
- NCT06533332
- Testing
- ERX-315
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- EtiraRx Australia Pty Ltd
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Bile Duct Carcinoma
- Trial name
- NCT03507998
- Testing
- CGX1321
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Curegenix Inc.
Mitral Regurgitation
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in…
- Trial name
- APOLLO-EU (NCT05496998)
- Testing
- Medtronic Intrepid™ TMVR TF System
- Where
- 37 sites in Denmark, France and 6 more
- Volunteers
- 400 people
- Sponsor
- Medtronic Cardiovascular
Pancreatic Surgery, Pancreatic Duct Stenting
Pancreatic Stent to Prevent Leak After Distal Pancreatectomy
The purpose of this study is to investigate an intervention to prevent complications after pancreas surgery. The goal is to determine if placing a stent into the pancreatic duct before surgery will decrease or prevent leaking…
- Conditions
- Pancreatic Surgery, Pancreatic Duct Stenting, Pancreatic Cancer, Distal Pancreatectomy
- Trial name
- LEAPS (NCT00671463)
- Testing
- Pancreatic duct stenting
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00009893
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 19 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumors, HR+ Breast Cancer
(VELA) Study of BLU-222 in Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
- Conditions
- Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer
- Trial name
- NCT05252416
- Testing
- BLU-222, Carboplatin, Ribociclib
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Blueprint Medicines Corporation
Pancreatic Cancer
Clinical Study Evaluating the Effect of Losartan
The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion.
- Trial name
- NCT06539806
- Testing
- Losartan 50mg Tab
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Pancreatic Cancer
Is One Pass Enough for the Diagnosis of the Pancreatic Masses During EUS-FNB?
Endoscopic ultrasonography (EUS) with tissue acquisition (TA) is nowadays a well-established technique for the sampling of solid lesions pancreatic and non-pancreatic lesions.
- Trial name
- ONE PASS (NCT05436704)
- Testing
- EUS-FNB
- Where
- Italy
- Volunteers
- 79 people
- Sponsor
- Istituto Clinico Humanitas Mater Domini
Advanced Solid Tumors, Colorectal Cancer (CRC)
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
- Trial name
- NCT07542704
- Testing
- KQB368
- Volunteers
- 48 people
- Sponsor
- Kumquat Biosciences Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)